4D MOLECULAR THERAPEUT

4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™

16 فبراير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference

08 فبراير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

02 فبراير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference

21 نوفمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

14 نوفمبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022

10 نوفمبر 2022 16:05:01 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results

09 نوفمبر 2022 16:05:02 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022

03 نوفمبر 2022 09:45:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022

26 أكتوبر 2022 16:05:01 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

27 سبتمبر 2022 16:10:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

20 سبتمبر 2022 16:15:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update

11 أغسطس 2022 16:03:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences

02 يونيو 2022 16:02:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

12 مايو 2022 16:01:01 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

05 مايو 2022 16:02:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis

04 أبريل 2022 16:02:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

28 مارس 2022 16:02:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company’s Board of Directors

22 فبراير 2022 16:02:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

11 فبراير 2022 16:03:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium

09 فبراير 2022 08:02:00 بحسب Nasdaq GlobeNewswire